drugset
drugset / Trial / NCT02214914

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

NCT02214914 ↗

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

First evaluation of safety, tolerability, pharmacokinetics and the pharmacodynamic effect of BI 11634 on coagulation parameters

Timeline

Start
2006-11
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 11634 Unknown 5 mg Oral
Subject BI 11634 Unknown 10 mg Oral
Subject BI 11634 Unknown 25 mg Oral
Subject BI 11634 Unknown 50 mg Oral
Subject BI 11634 Unknown 100 mg Oral
Subject BI 11634 Unknown 200 mg Oral
Subject BI 11634 Unknown 400 mg Oral

Indications

No indication recorded.